Study Notes on Patenting, Drug Testing, and Clinical Trials

CENTENNIAL COLLEGE - BI 209 - Pharmaceutical Microbiology Lecture 4: Patenting, Drug Testing and Clinical Trials

Overview of Patenting

  • Patent Purpose:

    • Provides innovators with limited market exclusivity.

    • In exchange for complete information about the invention.

  • Patenting Process in Pharmaceuticals:

    • Applications are submitted upon the onset of clinical trials.

    • Patents can be transferred or sold to third parties.

    • Importance of patents in pharmaceuticals:

    • Research and development (R&D) is lengthy, expensive, uncertain, and risky.

    • Patents are essential to ensure return on R&D investments.

    • Exclusivity duration for pharmaceutical inventions is 20 years from the patent application date.

    • Clinical trials typically shorten the duration of market exclusivity compared to other industries.

Criteria for Patentability

  • Overview of the criteria:

    • Novelty

    • Non-obviousness

    • Acceptable level of disclosure

    • Utility of invention

Legal Framework in Canada

  • Key components:

    • Patent Act and Patent Rules: Define the patent regime in Canada.

    • Patented Medicines (Notice of Compliance) Regulations (NOC Regulations): Facilitates patent linkage and balances interests between innovators and generic manufacturers.

    • Food and Drug Regulations: Ensure data exclusivity for innovators.

  • Patent applications are filed with the Canadian Intellectual Property Office (CIPO).

Novelty

  • Definition: The invention must be “new” as of the application date.

  • Requirements:

    • No prior public disclosure (i.e., publications, meetings).

    • One-year grace period provided for public disclosures made by inventors.

    • The invention must not be enabling to an average skilled person in the field.

  • System: First-to-file system applies in Canada.

Non-obviousness or Inventiveness

  • Definition: The invention should not be obvious to someone skilled in the art at the relevant date.

  • Implication: Must contain innovative elements beyond logical continuation of known processes.

Acceptable Level of Disclosure

  • The invention must be detailed sufficiently in the patent application so others can replicate it post-expiry.

Usefulness or Utility

  • The invention must demonstrate practical use, which must be controllable and reproducible.

Patent-Eligible Subject Matter

  • Possible Inventions:

    • Chemical or ingredients with medicinal applications.

    • Engineered organisms with enhanced properties.

    • Process vs. Product:

    • Focus on processes rather than just outcomes or final products.

    • Examples include methods that increase product yields in engineered cells.

Restrictions on Patentability

  • Naturally occurring organisms (including genetically modified organisms) cannot be patented.

  • Methods to create genetically modified organisms may be patented.

  • Purified biological materials can be patented if the purification achieves significant improvements in product quality.

  • Case Studies:

    • “Harvard mouse” case, 1993-2002, notable for patenting transgenic organisms.

Genetic Material and Patents

  • Eligible for Patenting:

    • Genes, DNA sequences, cell lines, plasmids, and vectors that are isolated or engineered.

    • Specific genetic applications are patentable (e.g., diagnostic markers).

  • Non-Eligibility:

    • Naturally occurring genetic materials are not patentable unless applied in a novel and useful way.

Regulatory Framework for New Drugs

Key Regulations

  • A new drug must undergo clinical trials to demonstrate safety and efficacy before approval by Health Canada.

  • Types of pharmaceuticals included:

    • Prescription and non-prescription drugs, radiopharmaceuticals, biologics, etc.

  • The Health Products and Food Branch (HPFB) is responsible for regulatory enforcement.